ABSTRACT
The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) varies considerably based on the disease and remission status at the time of transplantation.
Any retrospective or prospective HSCT study that enrolls patients across disease types must account for this heterogeneity; yet current methods are neither standardized nor validated. We conducted a retrospective study of 1539 patients who were transplanted at Dana-Farber Cancer Institute/Brigham and Women's Hospital from 2000 to 2009. Using multivariable models for overall survival (OS), we created the Disease Risk Index (DRI).
This tool uses readily available information about disease and disease status to categorize patients into 4 risk groups with significantly different OS and progression-free survival (PFS), based primarily on differences in the relapse risk. This scheme applies regardless of conditioning intensity, is independent of co-morbidity index, and was validated in an independent cohort of 672 patients from the Fred Hutchinson Cancer Research Center.
This simple and validated scheme could be used to risk-stratify patients in both retrospective and prospective HSCT studies; to calibrate HSCT outcomes across studies and centers; and to promote the design of HSCT clinical trials that enroll patients across diseases and disease states, increasing our ability to study non-disease-specific outcomes in HSCT.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) can be a curative option for a large number of hematologic malignancies, including acute and chronic leukemias as well as indolent and aggressive lymphoid neoplasms. However, the success of HSCT is heavily dependent on the disease and disease status at the time of transplantation [1] [2] [3] [4] [5] [6] . This creates a particular problem in studying and reporting HSCT outcomes because of the need to account for the heterogeneity of disease and disease status in a study cohort. This problem is akin to that of having to account for heterogeneity in co-morbidities or donor HLA match, which both influence HSCT outcome. In those two cases, accepted grouping schemes already exist 7, 8 , but in the case of disease and disease status there is at present no uniformly accepted scheme, even though the variability in HSCT outcome based on disease/status is very wide. For example, the survival for patients undergoing HSCT for chronic myelogenous leukemia (CML) in chronic phase is over 70% 9 , whereas that for patients undergoing HSCT for adverse karyotype AML not in complete remission is less than 20% 10 . It is therefore essential to account for this in any retrospective or prospective HSCT study that enrolls patients across diseases and disease stages.
Furthermore, given the major prognostic importance of cytogenetics for AML and MDS 11, 12 , it is critical that this information be included in a comprehensive disease/status grouping scheme. At present, most investigators stratify patients among disease/status groups by including a binary classification of "low" or "high" risk disease in multivariable models; the particular classifications vary across studies, usually reflecting the general experience of that transplant center [13] [14] [15] , and often ignore cytogenetics. An alternative strategy is to decrease the heterogeneity of the study population by restricting A validated scheme for stratifying patients by disease and disease status (disease/status) could find important uses in the design and interpretation of both retrospective and prospective studies. In the present study, we developed and validated such a disease/status scheme for adult HSCT patients based on a retrospective analysis of 2 large single-institution cohorts.
METHODS

Patients
The training set was comprised of 1539 consecutive adult patients who underwent their first HSCT with myeloablative or reduced intensity conditioning at Dana Farber Cancer Institute/Brigham and Women's Hospital (DFCI/BWH) within the 10-year period [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . Patients receiving transplantation for benign hematologic conditions were excluded. We also excluded 16 patients with very rare diseases (NK or large granular lymphocyte leukemia, mast cell leukemia, Burkitt or lymphoblastic lymphoma), or with more than 1 hematologic malignancy. For all patients, we collected pre-HSCT information and HSCT outcomes from our transplantation database, with independent confirmation of all disease and status information via a review of electronic medical records. We collected cytogenetics for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL), when such information was available in the medical 
Definitions
For AML and MDS, we classified cytogenetics according to HSCT-specific schemes described previously 11, 12 . Patients whose cytogenetics were unavailable (6% of patients in the training cohort and 4% of those in the testing cohort) were assigned to the intermediate risk category (as their outcomes were very similar). Of note, AML and MDS cytogenetics in the validation cohort were classified according to the SWOG/ECOG scheme 16 (and could not be reclassified since the primary data were not available for many of the patients). For CLL, we considered del(17p), del(11q) and complex as adverse; for ALL, we considered t(9;22), t(4;11) and complex as adverse.
However, cytogenetics did not affect HSCT outcome for CLL or ALL; the hazard ratio for mortality associated with adverse cytogenetics (compared to intermediate) was 1.1 (p=0.9) for CLL and 0.9 (p=0.5) for ALL in the multivariable model. Therefore, all cytogenetics categories were grouped together in the final models for those 2 diseases.
We sub-classified non-Hodgkin lymphoma (NHL) as described in 
Statistical Analysis
Patient baseline characteristics were reported descriptively. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method. OS was defined as the time from stem cell infusion to death from any cause. Patients who were alive or lost to follow-up were censored at the time last seen alive. PFS was defined as the time from stem cell infusion to disease relapse or progression or death from any cause, whichever occurred first. Patients who were alive without disease relapse or progression were censored at the time last seen alive and progression-free. The log-rank test was used for comparisons of Kaplan-Meier curves. Cumulative incidence curves for non-relapse death and relapse with or without death were constructed reflecting time to relapse and time to non-relapse death respectively as competing risks. Time to relapse and time to non-relapse death were measured from the date of stem cell infusion. The difference between cumulative incidence curves in the presence of a competing risk was tested using the Gray method 17 . Potential prognostic factors for OS, PFS, relapse, and non-relapse mortality (NRM) were examined in the proportional hazards model as well as in the competing risks regression model 18 . The variables considered are detailed in Table   4 . The proportional hazards assumption for each variable of interest was tested and interaction terms were examined. The linearity assumption for continuous variables was examined using restricted cubic spline estimates of the relationship between the continuous variable and log relative hazard 19 and the cutoff points of these variables were based on the change of the log relative hazards. All p-values are two-sided with a significance level of 0.05. All calculations were done using SAS 9.3 (SAS Institute Inc, Cary, NC), and R version 2.13.2 (the CRAN project).
RESULTS
Patient Characteristics in the Training Set
The baseline characteristics of the 1539 patients in the training set are shown in Table 1 .
Eight-hundred and twelve patients (53%) underwent myeloablative conditioning (MAC), 47% reduced intensity conditioning (RIC). The median age was 49 (range, 18-73). AML was the most common disease (37% of patients). Twenty-nine percent of patients were in first CR (CR1) at the time of transplant; the frequencies of other diseases and stages are shown in the table. Forty percent of patients underwent transplantation from HLAmatched related donors (MRD), while 45% were transplanted from HLA-matched unrelated donors (MUD), and 15% received HLA-mismatched transplantation (including 6% of patients who received DUCB products). Eighty percent of patients received stem cells harvested from peripheral blood (PB), and the majority (96%) received graft-versushost-disease (GVHD) prevention regimens that included a calcineurin inhibitor (CI).
Median follow-up for survivors was 4 years.
Derivation of the Disease/Status Groups
We constructed Cox proportional hazards models for OS using disease and status that included the following variables: age, gender of donor and recipient, donor type and HLA match, graft source, CMV serostatus of donor and recipient, GVHD prophylaxis regimen, therapy-related or transformed disease, Flt3-ITD status for AML (when available), year of transplantation, whether treatment was done on or off a clinical trial. Initially, separate models were built for the MAC and RIC patients. Because graft source and year of HSCT violated the proportional hazards assumption, the models were stratified according For personal use only. on October 22, 2017. by guest www.bloodjournal.org From to both variables. Diseases that were underrepresented in one of the two groups (multiple myeloma, myeloproliferative neoplasms, mantle cell lymphoma, T-cell lymphomas, Hodgkin lymphoma) were excluded in this step. Based on the hazard ratios (HRs) for mortality associated with each disease and with each status, with cutoffs of 0.67 and 1.5, a disease grouping scheme and a status grouping scheme were created within each conditioning group. The choice of those HR cutoffs was mostly based on the fact that in our models, this seemed to correspond roughly to the threshold of statistical significance, with almost all differences above that level significant and none under that level significant. Remarkably, the disease grouping schemes were identical for MAC and RIC groups. The status schemes were almost identical, with the exception of 2 nd or subsequent PR (PR2+), which fell into the intermediate-risk group for RIC and into the high-risk group for MAC. Based on this, the RIC and MAC cohorts were combined to assign the rarer diseases to the appropriate risk groups.
The preceding steps yielded a three-group disease risk scheme and a two-group status risk scheme for MAC patients, generating 6 possible combinations of disease and status (Table 2 ). Of note, there was no significant interaction between disease and status risk in the multivariable models. The OS of patients in each of these 6 MAC disease/status groups are shown in Figure 1A . As can be seen from the figure, and confirmed in multivariable models, the 6 combinations could be collapsed into 4 distinct groups (Table   3 ). Similarly, the RIC patients could also be assigned to one of 3 disease and one of 2 status risk groups (Table 2) , again generating 6 possible combinations, whose OS is plotted in Figure 1B . As with the MAC groups, the 6 RIC groups could easily be collapsed into 4 groups (Table 3 ). In the last step, the MAC and RIC cohorts were recombined, and patients were assigned to the appropriate disease/status group based on the above (see Tables 2 and 3 ). Figure 1C shows the OS of the patients within each group and for each conditioning intensity. It is apparent from the figure, and again confirmed in multivariable models, that the MAC and RIC risk groups had nearly identical outcomes, justifying the assignment of all patients, regardless of conditioning intensity, to one of 4 disease/status risk groups.
Performance of the Disease/Status Grouping Scheme
As illustrated in Table 3 and Figure 2A , this scheme stratified patients into 4 groups with very different rates of OS (4-year (4y) OS 64% in the low risk group (which comprised 15% of patients), 46% in the intermediate group (55% of patients), 26% in the high risk group (27% of patients), and 6% in the very high risk group (3% of patients); p<0.0001).
In the multivariable model (Table 4) , compared to the intermediate group, the HR for mortality associated with low-risk disease/status was 0.6 (p<0.0001), high-risk 1.8 (p<0.0001), and very high risk 3.1 (p<0.0001). The groups were also very different in terms of PFS ( Figure 2B ), with 4y PFS ranging from 56% in the low-risk group to 6% in the very high risk group (p<0.0001), confirmed by multivariable analysis (Table 4) . The difference in outcome was driven entirely by a difference in the cumulative incidence of relapse, with no significant difference in NRM (Tables 3 and 4 , Figures 2C and 2D ).
Impact of Co-morbidities
We were able to calculate an HCT-CI 8 for 718 of the patients in our cohort (83% of the patients transplanted after January 2005). The median score for those patients was 1
(range, 0-9). The median HCT-CI of the patients whose data was collected retrospectively was 1 (range, 0-9), versus 0 (range, 0-6) for those whose data was collected prospectively (p=<0.0001 of 1-2 (compared to HCT-CI=0) was 1.2 (p=0.14), and for HCT-CI 3+ was 1.7 (p=0.0002). Therefore, the disease/status score and a high co-morbidity score (HCT-CI>2) were independently predictive of increased mortality.
Validation of the Disease/Status Scheme
In order to validate our scheme, we used an independent cohort of 672 patients transplanted at FHCRC between 2000 and 2006. Their baseline characteristics are also shown in Table 1 . Patients in the validation cohort were on average younger, much more likely to receive MAC, and more likely to receive stem cells from an HLA-matched related donor. We classified the 672 patients according to our disease/status grouping scheme. As shown in Figures 3A and 3B , the scheme stratified the patients successfully for both OS and PFS (p<0.001 for both).
For
DISCUSSION
We propose a new tool for stratifying HSCT patients by disease and disease status at the time of transplantation, which we term the Disease Risk Index (DRI). The DRI uses a combination of a ternary breakdown for disease type and a binary breakdown for remission status to assign patients to one of 4 risk categories that differ very significantly , a finding supported (without any a priori assumption) by our analysis. Similarly, it is clear that cytogenetics in AML and MDS are a very strong determinant of HSCT outcome 11, 16, 26, 27 , which our results also confirm, and which makes cytogenetics an essential part of any risk stratification. A disease stratification system by post-HSCT relapse risk has been previously proposed 28 , but was limited to patients undergoing non-myeloablative conditioning, and did not successfully stratify the patients for overall survival. The DRI is exclusively based on disease/status, and should be used alongside other prognostic variables, unlike global indices such as the EBMT score 29 or the PAM score 13 .
The DRI was by far the most important determinant of HSCT outcome in multivariable modeling, which was driven primarily by differences in the risk of relapse between the For personal use only. on October 22, 2017. by guest www.bloodjournal.org From groups. The stratification ability of the DRI was validated in an independent cohort from a separate institution. The outcomes in the validation cohort within each group were slightly different from those in the training cohort, which is likely explained by differences in the baseline characteristics of the patients, as well as differences in the classification scheme used for cytogenetics. However, this supports, in fact, the robust applicability of DRI across different cytogenetics grouping schemes used for AML and MDS. We also recognize that the validation cohort contained few patients undergoing RIC HSCT, and few patients with CLL, multiple myeloma, or lymphoma, which weakens our ability to validate those disease assignments. Further validation studies will be important to strengthen or refine this index, especially for rarer diseases.
A striking result in this analysis was the similarity of outcomes between MAC and RIC groups. We started with the assumption that the optimal disease/status grouping schemes would be different for MAC and RIC patients. In fact, even though the MAC and RIC groups were completely independently derived, they turned out to be nearly identical.
Moreover, when patients were stratified by DRI, the outcomes in the MAC and RIC groups were remarkably similar ( Figure 2C ). This offers a very general validation of the growing number of disease-specific studies suggesting that conditioning intensity is not a strong determinant of HSCT outcome [30] [31] [32] .
It is noteworthy that a high HCT-CI (which in general reflects a higher risk of NRM) remained prognostic independently of the DRI, implying that the 2 scores may be used simultaneously. Interestingly, the very high risk group appeared to have a higher risk of We have attempted to minimize the possible biases in this study by studying a large patient cohort, by manually reconfirming all the disease and status information obtained from our transplantation database, and by validating the scheme in a large independent external cohort. One limitation of the DRI is the broadness of its categories.
Undoubtedly distinct subgroups with different prognoses exist within each broad disease/status group. However, this simplicity may also be this scheme's strength. It has only 4 groups, is readily obtainable on any patient, using information that is routinely Transplantation physicians will find few surprises in our risk groups; this is in fact reassuring, as it implies that our cohort was large enough to eliminate the influence of unique populations. We chose overall survival as our primary endpoint because it is ultimately the most relevant clinical outcome. Not surprisingly, given the close relationship between PFS and OS after HSCT, the DRI had high stratification ability for PFS as well. In fact, we developed a grouping scheme for PFS as well (not shown), which turned out to be nearly identical to the DRI.
In summary, we propose the DRI as a simple system for risk-stratifying heterogeneous populations of HSCT patients into four risk groups based solely on disease and remission status at the time of transplantation. These four risk groups have significantly different risks of relapse, overall and progression-free survival; they apply regardless of conditioning regimen intensity, retain their prognostic relevance after stratifying by comorbidity index, and were validated in an external independent cohort. The DRI could be useful in a variety of settings: first, it could improve the quality of any HSCT study that examines the prognostic role of variables other than disease/status; second, it would facilitate the interpretation of single-arm studies when such studies are done across a variety of disease/status categories (e.g., a phase 2 study of new conditioning or GVHD prevention regimens); third, it could be used to calibrate HSCT outcome across transplant centers, as is done for the Stem Cell Therapeutic Outcomes Database (SCTOD); fourth, it For personal use only. on October 22, 2017. by guest www.bloodjournal.org From would provide a reliable way to prospectively stratify patients entering HSCT clinical trials that are not disease-specific (e.g., comparative trials of GVHD prevention regimens), which is critical based on the importance of disease/status for outcome; fifth, and perhaps even more importantly, it could actually promote the design of HSCT trials that are not disease-specific, by removing the obstacle of outcome variability introduced by disease/status heterogeneity, which could significantly increase the power and generalizability of the trials. H. T. K. designed the research, analyzed the data and edited the paper.
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